ERBB2 and cancer: Assessing frequencies of cardiotoxic cancer therapies, we found that 9.7% of patients received HER2-targeting agents (CHIP: 5.9%, no CHIP: 14%, p = 0.6), 38% received anthracyclines (CHIP: 38%, no CHIP: 39%, p > 0.9), and 43% received chest radiation therapy (CHIP: 44%, no CHIP: 39%, p = 0.8).